Ziccum AB (publ) has signed an Evaluation agreement with a Biopharmaceutical Corporation focused on mRNA technologies. This new agreement is for a fully financed Feasibility study, formulating and drying mRNA/LNP materials with LaminarPace ambient drying. The agreement is the result of keen interest in the LaminarPace technology to generate dry powder materials in mRNA/LNP technology development.

This is based on successful results on the mRNA/LNP platform for LaminarPace, an entirely new drying technology making dry powder biopharmaceuticals possible. The Feasibility study is expected to start in May 2023. Lindahl acted as legal advisor to Ziccum AB (publ).